Skip to main content

The Implications of Positive Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer

World Journal of Surgery volume 36, pages 2187–2191 (2012)Cite this article

Abstract

Background

The clinical implications of peritoneal lavage cytology (CY) status in patients with potentially resectable pancreatic cancer have not been established.

Method

We retrospectively reviewed clinical data from 254 consecutive patients who underwent macroscopically curative resection for pancreatic cancer from February 2003 to December 2010 in our institution. Correlations between CY status and survival and clinicopathological findings were investigated.

Results

Of the 254 patients, 20 were CY+ (7.9 %). There were no significant differences between CY+ and CY− patients in background data (age, sex, the level of preoperative tumor marker, and adjuvant chemotherapy). Patients with positive serosal invasion were more likely to be CY+ than those with negative serosal invasion (P < 0.001) by univariate analysis. The median overall survival of CY+ patients and CY− patients was 23.8 months (95 % CI = 17.6–29.8) and 26.5 months (95 % CI = 20.7–32.3), respectively (P = 0.302). The median recurrence-free survival of CY+ and CY− patients was 8.1 months (95 % CI = 0.0–17.9) and 13.5 months (95 % CI = 11.5–15.5), respectively (P = 0.089).

Conclusion

CY+ status without other distant metastasis does not necessarily preclude resection in patients with pancreatic cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236

    PubMed  Article  Google Scholar 

  2. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267

    PubMed  Article  Google Scholar 

  3. Aletti GD, Gallenberg MM, Cliby WA et al (2007) Current management strategies for ovarian cancer. Mayo Clin Proc 82:751–770

    PubMed  Google Scholar 

  4. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112

    Article  Google Scholar 

  5. American Joint Committee on Cancer (2010) Exocrine and endocrine pancreas. In: The AJCC Cancer Staging Manual, 7th ed. Springer, New York, pp 241–249

  6. Clark CJ, Traverso LW (2010) Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg 199:657–662

    PubMed  Article  Google Scholar 

  7. Fernandez-del Castillo C, Rattner DW, Warshaw AL (1995) Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 82:1127–1129

    PubMed  Article  CAS  Google Scholar 

  8. Jimenez RE, Warshaw AL, Fernandez-Del Castillo C (2000) Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg 7:15–20

    PubMed  Article  CAS  Google Scholar 

  9. Leach SD, Rose JA, Lowy AM et al (1995) Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery 118:472–478

    PubMed  Article  CAS  Google Scholar 

  10. Makary MA, Warshaw AL, Centeno BA et al (1998) Implications of peritoneal cytology for pancreatic cancer management. Arch Surg 133:361–365

    PubMed  Article  CAS  Google Scholar 

  11. Merchant NB, Conlon KC, Saigo P et al (1999) Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 188:421–426

    PubMed  Article  CAS  Google Scholar 

  12. Meszoely IM, Lee JS, Watson JC et al (2004) Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. Am Surg 70:208–213 discussion 213–204

    PubMed  Google Scholar 

  13. Nakao A, Fujii T, Sugimoto H et al (2006) Oncological problems in pancreatic cancer surgery. World J Gastroenterol 12:4466–4472

    PubMed  Google Scholar 

  14. Warshaw AL (1991) Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 161:26–29 discussion 29–30

    PubMed  Article  CAS  Google Scholar 

  15. Yachida S, Fukushima N, Sakamoto M et al (2002) Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg 89:573–578

    PubMed  Article  CAS  Google Scholar 

  16. Yamada S, Takeda S, Fujii T et al (2007) Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Ann Surg 246:254–258

    PubMed  Article  Google Scholar 

  17. Ueno H, Kosuge T, Matsuyama Y et al (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908–915

    PubMed  Article  CAS  Google Scholar 

  18. Tempero MA, Arnoletti JP, Behrman S et al (2010) Pancreatic adenocarcinoma. J Natl Compr Cancer Netw 8:972–1017

    CAS  Google Scholar 

  19. Ferrone CR, Haas B, Tang L et al (2006) The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg 10:1347–1353

    PubMed  Article  Google Scholar 

  20. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

    PubMed  Article  CAS  Google Scholar 

  21. Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846 discussion 846–838

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant-in-aid for cancer research from the Ministry of Health, Welfare and Labor of Japan and by the Japanese Foundation for Promotion of Cancer Research.

Conflict of interest

The authors declare no personal conflict of interest and no financial support for the study.

Author information

Affiliations

  1. Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Ryuji Yoshioka, Akio Saiura, Rintaro Koga, Junichi Arita, Nobuyuki Takemura, Yoshihiro Ono & Toshiharu Yamaguchi

  2. Department of Hepato-Biliary-Pancreatic Surgery, National Defense Medical College Hospital, Tokorozawa, Japan

    Junji Yamamoto

Authors
  1. Ryuji Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akio Saiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rintaro Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junichi Arita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuyuki Takemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihiro Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Junji Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshiharu Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akio Saiura.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yoshioka, R., Saiura, A., Koga, R. et al. The Implications of Positive Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer. World J Surg 36, 2187–2191 (2012). https://doi.org/10.1007/s00268-012-1622-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-012-1622-0

Keywords

  • Pancreatic Cancer
  • Curative Resection
  • Invasive Ductal Carcinoma
  • National Comprehensive Cancer Network
  • National Comprehensive Cancer Network